CD8A and colorectal carcinoma: Complementary innovations in nanotechnology have enabled mitochondrial-targeted nanoinducers (mitoNIDs) that disrupt redox balance and potentiate the activity of CAR-T and CD8+ T cells, offering new hope for immunotherapy-refractory MSS CRC (27).